Literature DB >> 8486040

Time course of hemostatic abnormalities in sepsis and its relation to outcome.

J A Lorente1, L J García-Frade, L Landín, R de Pablo, C Torrado, E Renes, A García-Avello.   

Abstract

OBJECTIVES: To investigate the time course and the relation to prognosis of coagulation and fibrinolytic abnormalities in patients with septic shock. PATIENTS AND METHODS: Forty-eight consecutive patients admitted to the medical ICU with the diagnosis of septic shock (diagnosed by defined criteria) were studied. Mortality was 25 of 48. Mean age was 57 +/- 7.3 years. Blood samples were obtained on days 1, 4, and 7 after hospital admission to measure tissue-type plasminogen activator antigen (t-PA), urokinase-type plasminogen activator (u-PA), plasminogen activator inhibitor antigen (PAI-1), plasminogen, alpha 2-antiplasmin, fibrinogen, antithrombin III, protein C, protein S, thrombin-antithrombin complexes (TAT), D-dimer, and von Willebrand factor-related antigen (vWF:Ag).
RESULTS: All patients showed marked abnormalities in both the coagulation and fibrinolytic systems. There were signs of coagulation activation and elevation of both activators and inhibitors of fibrinolysis. Nonsurvivors showed lower levels of protein C and antithrombin III and higher concentration of TAT than survivors. While both t-PA and PAI-1 concentrations were high in survivors and nonsurvivors, only survivors showed a progressive normalization of both parameters during the study period. Low plasminogen levels and plasminogen/alpha 2-antiplasmin ratio were found in both groups, presenting a trend toward normalization only in survivors. The differences reported were not apparent at the time of hospital admission.
CONCLUSIONS: Septic shock is characterized by coagulation activation and fibrinolysis activation and inhibition. Nonsurvivors present a particular hemostatic profile characterized by a more marked activation of coagulation and a more intense inhibition of fibrinolysis. None of the abnormalities studied was significantly different between survivors and nonsurvivors at the time of hospital admission. In the presence of fibrin formation, nonsurvivors present a maintained imbalance in the fibrinolytic response determined by higher PAI-1 plasma concentration, probably contributing to their poor outcome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486040     DOI: 10.1378/chest.103.5.1536

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  56 in total

1.  Treatment of sepsis with activated protein C.

Authors:  C J Hinds
Journal:  BMJ       Date:  2001-10-20

Review 2.  Emerging therapies in severe sepsis.

Authors:  S J Finney; T W Evans
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 3.  Coagulation in sepsis.

Authors:  André Amaral; Steven M Opal; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2004-05-18       Impact factor: 17.440

4.  Protein S modulates the anticoagulant action of recombinant human activated protein C: a comparison between neonates and adults.

Authors:  Gerhard Cvirn; Martin Koestenberger; Bettina Leschnik; Christoph Male; Joerg Kutschera; Ulrika Ferstl; Wolfgang Muntean; Guenther Juergens; Siegfried Gallistl
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

5.  When acquired thrombophilia mattered.

Authors:  J S Hammond; L Jackson; A B Zaitoun; B J Rowlands; G P Aithal
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

6.  Plasma derived protein C in severe sepsis: report of two cases.

Authors:  A Tuttolomondo; A Pinto; D Di Raimondo; P Fernandez; G Licata
Journal:  Intern Emerg Med       Date:  2008-02-09       Impact factor: 3.397

Review 7.  Antithrombin III and sepsis.

Authors:  E F Mammen
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

8.  Guidance on patient identification and administration of recombinant human activated protein C for the treatment of severe sepsis.

Authors:  Gary Garber; Rt Noel Gibney; Bruce Light; Claudio Martin; Kenneth Cunningham; Jean-Gilles Guimond; Sheldon Magder; James Russell
Journal:  Can J Infect Dis       Date:  2002-11

9.  Biomarkers of endothelial cell activation in early sepsis.

Authors:  Simon Skibsted; Alan E Jones; Michael A Puskarich; Ryan Arnold; Robert Sherwin; Stephen Trzeciak; Philipp Schuetz; William C Aird; Nathan I Shapiro
Journal:  Shock       Date:  2013-05       Impact factor: 3.454

10.  Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock.

Authors:  H Bryant Nguyen; Manisha Loomba; James J Yang; Gordon Jacobsen; Kant Shah; Ronny M Otero; Arturo Suarez; Hemal Parekh; Anja Jaehne; Emanuel P Rivers
Journal:  J Inflamm (Lond)       Date:  2010-01-28       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.